Little Rock, ARNCT06524830Now EnrollingIRB Ready

Treatment Resistant Depression Clinical Trial in Little Rock, AR

Access cutting-edge treatment resistant depression treatment through this phase 2 clinical trial at a research site in Little Rock. Study-provided care at no cost to qualified participants.

Sponsored by atai Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Little Rock location

Preparing your pre-screening questions…

Expert Care in Little Rock

Access treatment resistant depression specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related treatment resistant depression treatment provided free

Apply for This Little Rock Location

Check if you qualify for this treatment resistant depression clinical trial in Little Rock, AR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Little Rock

    Convenient for AR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Little Rock site if eligible
  4. 4Begin participation

About This Treatment Resistant Depression Study in Little Rock

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.

Sponsor: atai Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Participant must be 18 to 65 years of age inclusive at the time of signing the Informed Consent.
Has a diagnosis of recurrent moderate or severe MDD without psychotic features or single- episode MDD with duration greater than or equal to 3 months without psychotic features and is currently experiencing a major depressive episode.
Onset of first episode of MDD occurred before age 55.
Has not responded to an adequate dose and duration of at least two and no more than five antidepressant medications for the current depressive episode, as determined by the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH- ATRQ).
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.

Exclusion Criteria

Has a current or prior DSM-5-TR diagnosis of a schizophrenia spectrum and other psychotic disorder, substance/medication-induced psychotic disorder, bipolar and related disorder, or any disorder with psychotic features.
Has a moderate or severe substance use disorder (drug, alcohol, or tobacco) within the 6 months before Screening and/or history of moderate or severe substance use disorder (drug alcohol) within the previous 1 year before Screening
Has a history of, or current signs and symptoms of, diseases or conditions that would make participation not be in the best interest (e.g., compromise the wellbeing) of the participant or that could prevent, limit, or confound the protocol-specified assessments.
Has suicidal ideation with some intent to act within 6 months before Screening or a history of suicidal behavior within the past 1 year before Screening.
Has a history of clinically significant cardiovascular, cerebrovascular, or peripheral vascular disease or condition, including but not limited to unstable angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, valvular heart disease, obstructive coronary artery disease, hypertension, hypotension, bradycardia, tachycardia, or risk factors for long QT Syndrome.
Has an active malignancy, or history of malignancy, excluding basal or squamous cell carcinoma of the skin, within 2 years before Screening.
Has any known allergy or hypersensitivity to VLS-01 or to any of the excipients in the formulation.
Has recently initiated and is currently undergoing directive psychotherapy (e.g., cognitive behavioral therapy, interpersonal psychotherapy, psychodynamic psychotherapy) within the past 30 days before Screening. Participants planning to initiate individual or group therapy during the study are also not eligible.
Has received any prohibited therapies.
Has clinically significant laboratory abnormalities at Screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Little Rock?

Yes, this clinical trial (NCT06524830) has an active research site in Little Rock, AR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Treatment Resistant Depression Treatment Options in Little Rock, AR

If you're searching for treatment resistant depression treatment options in Little Rock, AR, this clinical trial (NCT06524830) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Little Rock research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced treatment resistant depression specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all treatment resistant depression clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Little Rock, AR

See all depression clinical trials recruiting in Little Rock — not just this study.

Browse Depression Trials in Little Rock →

Browse More Trials by Condition

Depression TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Little Rock?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Little Rock, AR